Volume 5 Issue 5, May 2021

The phagocytic clearance of the large fraction of transplanted cells that typically undergo rapid cell death contributes to therapeutic outcomes.

The restoration of a local chemokine gradient by nanoparticles non-covalently anchored on the surface of systemically administered red blood cells delays cancer progression in mouse models of lung metastasis.

The enhanced accumulation and residence time of systemically administered interleukin-4 fused to serum albumin in lymph nodes and in the spleen prevents the development of multiple sclerosis in mice.

CAR-T cells specific for a neoantigen derived from the driver oncogene nucleophosmin display potent and specific cytotoxic activity in mouse models of human acute myeloid leukaemia.

The sustained release of a leukaemia-associated epitope peptide and of anti-PD-1 antibody co-encapsulated in degradable microcapsules results in superior therapeutic outcomes in mouse models of leukaemia.

T cells derived from human induced pluripotent stem cells lacking certain components of the human leukocyte antigen system and incorporating a ligand that inhibits natural killer cells escape rejection when implanted in allogeneic mice.

The systemic administration of erythrocytes with chemokine-encapsulating nanoparticles non-covalently anchored to their surface results in local and systemic tumour suppression in mouse models of lung metastasis.

A polyvalent STING agonist prolongs the activation of innate-immunity pathways through the formation of STING condensates, and leads to synergistic therapeutic outcomes in vivo when combined with the STING ligand cGAMP.

Mimicking the molecular architecture of channel-forming membrane proteins of a target microbe can be used to design host defence peptides that specifically target a particular pathogen, as shown here for Mycobacterium tuberculosis.